Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs

Luo, Jiesi; Qin, Lingfeng; Zhao, Liping; Gui, Liqiong; Ellis, Matthew W.; Huang, Yan; Kural, Mehmet H.; Clark, Janet A.; Ono, Shun; Wang, Juan; Yuan, Yifan; Zhang, Shang Min; Cong, Xiangyu; Li, Guangxin; Riaz, Muhammad; Lopez, Colleen A.; Hotta, Akitsu; Campbell, Stuart G.; Tellides, George; Dardik, Alan; Niklason, Laura E.; Qyang, Yibing

doi:10.1016/j.stem.2019.12.012

Cited by 121 publications

(114 citation statements)

References 41 publications

Supporting

Mentioning

111

Contrasting

Unclassified

Order By: Relevance

“…In contrast, human iPSCs have less ethical and social issues compared to human ESCs [24,25]. Human iPSCs are produced by the manipulation of differentiated somatic cells [26][27][28][29]. Reprogramming of human somatic cells through the ectopic expression of transcription factors has provided a new avenue for disease modeling and regenerative medicine [16,30].…”

Section: Introductionmentioning

confidence: 99%

Differentiation of human induced pluripotent stem cells into erythroid cells

et al. 2020

View full text Add to dashboard Cite

During the last years, several strategies have been made to obtain mature erythrocytes or red blood cells (RBC) from the bone marrow or umbilical cord blood (UCB). However, UCB-derived hematopoietic stem cells (HSC) are a limited source and in vitro large-scale expansion of RBC from HSC remains problematic. One promising alternative can be human pluripotent stem cells (PSCs) that provide an unlimited source of cells. Human PSCs, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), are self-renewing progenitors that can be differentiated to lineages of ectoderm, mesoderm, and endoderm. Several previous studies have revealed that human ESCs can differentiate into functional oxygen-carrying erythrocytes; however, the ex vivo expansion of human ESC-derived RBC is subjected to ethical concerns. Human iPSCs can be a suitable therapeutic choice for the in vitro/ex vivo manufacture of RBCs. Reprogramming of human somatic cells through the ectopic expression of the transcription factors (OCT4, SOX2, KLF4, c-MYC, LIN28, and NANOG) has provided a new avenue for disease modeling and regenerative medicine. Various techniques have been developed to generate enucleated RBCs from human iPSCs. The in vitro production of human iPSC-derived RBCs can be an alternative treatment option for patients with blood disorders. In this review, we focused on the generation of human iPSC-derived erythrocytes to present an overview of the current status and applications of this field.

show abstract

Section: Introductionmentioning

confidence: 99%

Differentiation of human induced pluripotent stem cells into erythroid cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…To our knowledge, there have been limited applications of iPSCbased TEVGs, let alone in the context of aortic disease. In one case at least, TEVGs demonstrated mechanical strength comparable to that of native veins; when implanted in rats, they showed sustained mechanical function and patency (Sundaram et al, 2014;Luo et al, 2020). While the application of iPSCderived VSMCs in regenerative medicine for the treatment of aortic disease is attractive, we would like to caution that this represents a very labor-intensive task.…”

Section: Regenerative Medicinementioning

confidence: 99%

“…The timeline grows even longer if gene editing also has to be involved. As an alternative, haplotype matched/allogenic iPSCs, MSCs or ESCs could be used providing the advantage of well-defined VSMC differentiation protocols but without needing to develop individual lines and grafts specifically for each patient (Sundaram et al, 2014;Gui et al, 2016;Elliott et al, 2019;Luo et al, 2020). These can be prepared in a variety of formats, including printed, electrospun,or decellularized scaffold grafts.…”

Section: Regenerative Medicinementioning

confidence: 99%

Aortic “Disease-in-a-Dish”: Mechanistic Insights and Drug Development Using iPSC-Based Disease Modeling

Davaapil

Shetty

Sinha

2020

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Thoracic aortic diseases, whether sporadic or due to a genetic disorder such as Marfan syndrome, lack effective medical therapies, with limited translation of treatments that are highly successful in mouse models into the clinic. Patient-derived induced pluripotent stem cells (iPSCs) offer the opportunity to establish new human models of aortic diseases. Here we review the power and potential of these systems to identify cellular and molecular mechanisms underlying disease and discuss recent advances, such as gene editing, and smooth muscle cell embryonic lineage. In particular, we discuss the practical aspects of vascular smooth muscle cell derivation and characterization, and provide our personal insights into the challenges and limitations of this approach. Future applications, such as genotype-phenotype association, drug screening, and precision medicine are discussed. We propose that iPSC-derived aortic disease models could guide future clinical trials via "clinical-trials-in-a-dish", thus paving the way for new and improved therapies for patients.

show abstract

“…B. Qyang, 2015b; Klein, 2018; Maguire, Xiao, & Xu, 2017). The hiPSC-VSMCs in pure population have been generated in abundance (Cheung, Bernardo, Trotter, Pedersen, & Sinha, 2012; Dash et al, 2015b; Dash et al, 2016; Patsch et al, 2015) and their ability to carry the disease mutations and to secrete collagen has been used to develop robust disease models (Atchison et al, 2020; Atchison, Zhang, Cao, & Truskey, 2017; Dash et al, 2016; Ge et al, 2012; Liu et al, 2011; Zhang et al, 2011) and vascular grafts (Gui et al, 2016; Karamariti et al, 2013; Luo et al, 2020), respectively. In addition, we recently reported the secretion of various growth factors and cytokines from these cells (Dash et al, 2020; Gorecka et al, 2020).…”

Section: Introductionmentioning

confidence: 99%

An In situ Collagen-HA Hydrogel System Promotes Survival and Preserves the Proangiogenic Secretion of hiPSC-derived Vascular Smooth Muscle Cells

Dash

Duan

Kyriakides

et al. 2020

Preprint

View full text Add to dashboard Cite

Human induced pluripotent stem cell-derived vascular smooth muscle cells (hiPSC-VSMCs) with proangiogenic properties have huge therapeutic potential. While hiPSC-VSMCs have already been utilized for wound healing using a biomimetic collagen scaffold, an in situ forming hydrogel mimicking the native environment of skin offers the promise of hiPSC-VSMC mediated repair and regeneration. Herein, the impact of a collagen type-I-hyaluronic acid (HA) in situ hydrogel crosslinked using a PEG based cross-linker on hiPSC-VSMCs viability and proangiogenic paracrine secretion was investigated. Our study demonstrated increases in cell viability and maintenance of proangiogenic growth factor secretion. The optimally cross-linked and functionalized collagen type-I/HA hydrogel system developed in this study shows promise as an in situ hiPSC-VSMC carrier system for wound regeneration.

show abstract

Tissue-Engineered Vascular Grafts with Advanced Mechanical Strength from Human iPSCs

Cited by 121 publications

References 41 publications

Differentiation of human induced pluripotent stem cells into erythroid cells

Differentiation of human induced pluripotent stem cells into erythroid cells

Aortic “Disease-in-a-Dish”: Mechanistic Insights and Drug Development Using iPSC-Based Disease Modeling

An In situ Collagen-HA Hydrogel System Promotes Survival and Preserves the Proangiogenic Secretion of hiPSC-derived Vascular Smooth Muscle Cells

Contact Info

Product

Resources

About